MIRM Mirum Pharmaceuticals Inc

0.00 (0.0%)
Pre Market
Last Updated: 04:00:07
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 0
Bid Price 31.32
Ask Price 34.95
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Mirum Pharmaceuticals Inc MIRM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 31.56 04:00:07
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 17.315 - 33.3934
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 31.56 USD

Mirum Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.21B 38.30M - 77.06M -135.67M -3.54 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Mirum Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MIRM Message Board. Create One! See More Posts on MIRM Message Board See More Message Board Posts

Historical MIRM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week31.9332.1230.2230.95364,894-0.37-1.16%
1 Month26.4933.393426.0030.91785,5335.0719.14%
3 Months26.2433.393424.2328.12601,7235.3220.27%
6 Months23.1133.393421.83527.07594,7558.4536.56%
1 Year22.5033.393417.31524.80470,9739.0640.27%
3 Years18.6033.393412.8222.91277,24512.9669.68%
5 Years13.0033.39346.512622.13234,40118.56142.77%

Mirum Pharmaceuticals Description

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.